This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Altria-Juul Tie-Up News Puts Consumer Staple ETFs in Focus
by Zacks Equity Research
Altria is in talks with e-cigarette maker Juul for acquiring a minority stake, putting consumer staple ETFs in focus.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $56.77 in the latest trading session, marking a -0.89% move from the prior day.
Juul Burns Out: Company Ends Sales & Social Media Promotions
by Nimah Quadri
It was a long time coming, but the $15 billion startup that had 70% market share of the e-cig industry has faced the consequences.
The Zacks Analyst Blog Highlights: Altria, American Express, U.S. Bancorp, T-Mobile and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, American Express, U.S. Bancorp, T-Mobile and Humana
Top Stock Reports for Altria, American Express & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), American Express (AXP) and U.S. Bancorp (USB).
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $64.63, marking a +1.51% move from the previous day.
ECigarette Company Juul Labs is Now Worth $15 Billion
by Madeleine Johnson
Juul is a booming e-cigarette company thanks to its popularity with teens and young adults.
Altria (MO) Q3 Earnings Top, Revenues Gain on Strong Pricing
by Zacks Equity Research
Altria's (MO) Q3 performance reflects consistent gains from higher pricing in the smokeable and smokeless segments.
Altria (MO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 0.93% and 1.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Pricing & Smokeless Unit Aid Altria's (MO) Q3 Earnings?
by Zacks Equity Research
Altria's (MO) Q3 performance to gain from strong pricing and strength in low risk alternatives. However, declining cigarette volumes is a concern.
Altria (MO) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Altria, Coca-Cola, PepsiCo, Constellation and Canopy Growth
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, Coca-Cola, PepsiCo, Constellation and Canopy Growth
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $60.77, moving -1.09% from the previous trading session.
Cannabis Market Attracts U.S. Cigarette Makers As Well
by Zacks Equity Research
With a declining number of cigarette smokers in the United States, cigarette-makers are looking into opportunities in the fast-growing cannabis industry.
Philip Morris (PM) Q3 Earnings: Cigarette Woes Dim Prospects
by Zacks Equity Research
Philip Morris' (PM) Q3 performance to be hurt by lower cigarette sales volumes. Nevertheless, performance of RRPs is expected to be strong.
Altria to Explore Cannabis Prospects, Eyes Stake in Aphria
by Zacks Equity Research
Per media sources, Altria (MO) is planning to venture into the cannabis industry and acquire minority stakes in Aphria.
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
Altria (MO) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $62.92 in the latest trading session, marking a -0.29% move from the prior day.
Top Analyst Reports for Altria, U.S. Bancorp & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), U.S. Bancorp (USB) and Biogen (BIIB).
6 Defensive Stocks to Combat Rate Spike Fears
by Swarup Gupta
Since these also hold the promise of higher-than-average yields, investing in defensive stocks looks like a prudent option.
The Zacks Analyst Blog Highlights: Tilray, Raytheon, Boyd Gaming, Altria Group and Simply Good Foods
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Raytheon, Boyd Gaming, Altria Group and Simply Good Foods
Get Over Marijuana, Indulge in These 4 Sin Stocks Instead
by Tirthankar Chakraborty
Products and services of sin stocks are relatively inelastic and the very nature of their business ensures a steady stream of consumers, irrespective of market conditions.
Factors Likely to Shape Constellation Brands (STZ) Q2 Earnings
by Zacks Equity Research
Constellation Brands' (STZ) strength in beer business is likely to drive second-quarter fiscal 2019 results.
Can PepsiCo (PEP) Beat Earnings in Q3 Despite Soft CSD Trend?
by Zacks Equity Research
PepsiCo (PEP) is well positioned due to solid brand portfolio, product innovation and strong snacks business. However, shift of consumers' taste to non-carbonated drinks remains a headwind.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Visa, Verizon, Alphabet and Altria
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Visa, Verizon, Alphabet and Altria